GMAB — GENMAB A/S

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1434265 ·
Last close
$51.96
Market Cap
$31.95B
52W High
$59.97
52W Low
$23.62
ADV30
5,475,261
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,187,000,000 1,099,000,000 441,000,000 342,000,000 12,936,000,000 1,860,000,000 6,603,000,000
Jun 2026 1,155,000,000 1,071,000,000 407,000,000 303,000,000 12,515,000,000 1,503,000,000 6,558,000,000
Mar 2026 896,000,000 831,000,000 225,000,000 53,000,000 12,376,000,000 1,521,000,000 6,694,000,000
Dec 2025 1,058,000,000 977,000,000 243,000,000 31,000,000 12,873,000,000 1,715,000,000 7,026,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$875,000,000
Investing CF
$-5,588,000,000
Financing CF
$4,826,000,000
CapEx
$-32,000,000
Dividends Paid
—
Buybacks
$-96,000,000
EPS Diluted TTM
$1.77
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$4,801,000,000
Inventory
$30,000,000
Receivables
$1,298,000,000
ST Investments
$0
EBIT TTM
$1,155,000,000
Pretax Income TTM
$778,000,000
Interest Exp TTM
$377,000,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,131,000,064
EBITDA
$1,376,999,936
Free Cash Flow
$870,625,024
Enterprise Value
$23,148,085,248
Total Cash
$1,510,000,000
Total Debt
$5,272,999,936
Shares Out
614,902,540
Trailing EPS
$1.27
Book Value
$9.98
ROE
14.0%
ROA
8.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,720,000,000 1,250,000,000 963,000,000 12,873,000,000 7,026,000,000 5,847,000,000 1,186,000,000
Dec 2024 3,121,000,000 1,015,000,000 1,133,000,000 6,414,000,000 1,277,000,000 5,137,000,000 1,126,000,000
Dec 2023 2,390,000,000 772,000,000 631,000,000 5,232,000,000 545,000,000 4,687,000,000 1,071,000,000
Dec 2022 2,087,681,170 901,999,165 784,697,534 4,334,978,914 408,324,818 3,926,654,097 563,047,827

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.59

Max Pain — expiry 2026-12-18

max pain strike: $35.00 · spot: $50.97 · call oi: 32,087 · put oi: 10,264
Expected Move to 2026-12-18: ±$4.80 (9.42%) — implied range $46.17 – $55.77 · ATM straddle on $50.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RPRX Royalty Pharma plc $30.58B $68.68 —
ZTS Zoetis Inc. $33.92B $83.48 —
ROIV Roivant Sciences Ltd. $28.05B $38.71 —
INSM INSMED Inc $26.73B $121.86 —
UTHR UNITED THERAPEUTICS Corp $24.88B $584.10 —

News headlines (Yahoo Finance, 1h cache)

Grant of Restricted Stock Units and Warrants to Employees in Genmab
2026-11-18 19:40 · Yahoo
Genmab (CPSE:GMAB) Stock Could Be 47% Undervalued As Epcoritamab Approvals Expand
2026-11-13 13:13 · Yahoo
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2026-11-12 19:09 · Yahoo
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2026-11-10 20:32 · Yahoo
Is Genmab (CPSE:GMAB) Fully Priced After Holding 2026 Guidance Steady?
2026-11-08 13:13 · Yahoo
Genmab (GMAB) Q3 2026 Earnings Call Transcript
2026-11-06 16:16 · Yahoo
Moody’s lifts Genmab outlook to positive on pipeline progress, debt reduction
2026-11-06 16:02 · Yahoo
Genmab AS (GMAB) (Q3 2026) Earnings Call Highlights: Revenue Jumps 22% as Epkinly and Pipeline ...
2026-11-06 07:15 · Yahoo
What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
2026-11-05 20:14 · Yahoo
Genmab shares fall 3% after Q3 revenue slightly misses expectations
2026-11-05 18:07 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.